Welcome to our dedicated page for Encision SEC filings (Ticker: ECIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for hard facts on Encision’s patented AEM® safety tools before your next trade? Investors usually start by googling phrases like “Encision annual report 10-K simplified” or “Encision quarterly earnings report 10-Q filing,” hoping to spot product-liability disclosures, litigation updates and robotics-partnership details buried in hundreds of pages. Stock Titan gathers every document the moment it hits EDGAR, so “Encision SEC filings explained simply” is more than a promise—it’s a click away.
Our platform applies AI-powered summaries and red-flag detection to each form. Whether you type “Encision insider trading Form 4 transactions” or need “Encision Form 4 insider transactions real-time,” instant dashboards show who bought or sold, at what price, and how it compares to historical patterns. Prefer deep dives? “Encision earnings report filing analysis” and “understanding Encision SEC documents with AI” open annotated 10-Q and 10-K cross-links that surface revenue by surgical segment, FDA commentary and cash-burn trends.
Encision’s niche—preventing stray-energy burns—means material events often hinge on clinical studies, FDA feedback or robotics collaborations. That’s why you’ll also find “Encision 8-K material events explained,” a spotlight on any sudden disclosure affecting patient-safety claims, and “Encision proxy statement executive compensation” for insight into how leadership is incentivized around safety metrics. Use cases include:
- Tracking “Encision executive stock transactions Form 4” before earnings
- Comparing R&D spend quarter-over-quarter
- Monitoring device-recall language for risk assessment
No matter which question you ask— from “Encision annual report 10-K simplified” to “Encision 8-K material events explained” —Stock Titan delivers complete coverage, AI clarity, and real-time alerts you can trust.
Encision, Inc. announced that Gregory Trudel resigned from its board of directors and also stepped down as CEO, President and executive officer effective December 8, 2025. The company states that Mr. Trudel disagreed with the other board members on the future direction of the company and concluded it was best to resign, while emphasizing that, apart from this difference over future direction, his resignation did not stem from any dispute over current operations, policies or practices.
Following his departure, the board appointed long-time director Robert H. Fries as Interim President and CEO. Mr. Fries, age 77, has served on Encision’s board since 2003, is a certified public accountant (inactive), and has extensive finance and tax consulting experience with large public multinational companies, which the company cites as qualifications for his interim leadership role.
Encision Inc. (ECIA) reported an insider equity award to its chief executive officer and director, Brandon Shepard. On 11/18/2025, he received an option to buy 10,000 shares of Encision common stock at an exercise price of $0.25 per share, expiring on 02/17/2031. The award is reported as directly owned.
The option vests over time: 20% of the shares vest after the first year of service on 11/18/2026, and the remaining shares vest in 48 equal monthly installments thereafter. This filing documents the grant and outlines the vesting schedule but does not include any sales of stock.
Encision Inc. director equity grant: Director Brandon Shepard reported receiving a stock option award from Encision Inc. (ticker ECIA) on 11/18/2025. The option gives him the right to buy 10,000 shares of Encision common stock at an exercise price of $0.25 per share.
The option expires on 02/17/2031. The grant vests over time, with 33% vesting after the first year of service on 11/18/2026 and the remaining portion vesting in 36 equal installments thereafter. Following this transaction, Shepard beneficially owns 10,000 derivative securities directly.
Encision Inc. (ECIA) reported a new equity award to an executive. Vice President of Marketing Brandon Shepard received an option on 10,000 shares of Encision common stock on 11/18/2025 at an exercise price of $0.25 per share. The option expires on 02/17/2031. The award vests 20% after one year of service on 11/18/2026, with the remaining shares vesting in 48 equal installments thereafter, so the grant becomes exercisable gradually over time while he remains in service.
Encision Inc. (ECIA) reported a weaker quarter for the three months ended September 30, 2025. Total revenue was $1.53 million, down from $1.76 million a year ago, as product sales fell 10% to $1.48 million and service revenue decreased to $46,248 following a brief project suspension by a customer. Gross margin was 46% versus 47% a year earlier. The company posted a net loss of $267,833, compared with a $170,262 loss last year.
Cash declined to $71,731 from $257,433 at March 31, 2025. Working capital was $1.38 million, and current borrowings under the line of credit were $31,706 with up to $968,294 available, subject to eligible receivables. Management states there is substantial doubt about continuing as a going concern without additional financing, though a private placement on August 19, 2025 added $500,000 and increased shares outstanding to 16,879,645.
The quarter also reflected lower sales and marketing and G&A costs, offset by higher R&D. Disclosure controls were deemed not effective due to inadequate segregation of duties.
Encision, Inc. disclosed a board change. Director Patrick Pace resigned on October 30, 2025. The company stated the resignation was not the result of any dispute or disagreement regarding its operations, policies, or practices.
The filing records the change under Item 5.02 and was signed by Controller and Principal Accounting Officer Brandon Shepard.
FAQ
What is the current stock price of Encision (ECIA)?
What is the market cap of Encision (ECIA)?
